This analysis reveals genomic alterations in tumor tissue and plasma DNA in patients with ROS1 translocations, suggesting implications for treatment response.
Supplementary Figure 3. Genomic alterations detected in patients treated in subprotocol G enrolling patients with ROS1 translocations who received treatment with crizotinib. Patients are stratified according to the best overall response. Triangles are used to depict the presence of mutation in tissue (lower triangle) and/or plasma (upper triangle).
No takes yet. Share an insight, caveat, or question.
Gouda et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: